19 Assets held for sale

In the next fiscal year, the Carl Zeiss Meditec Group plans to sell its investment in Daoenke Medical Technology Co., Ltd., Shanghai, China, to the Carl Zeiss Group. This was previously presented as a non-consolidated company. The Supervisory Board of the parent company D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., Zuidland, Netherlands, approved the transaction in September 2025. The sale is expected in the first half of the 2025/26 fiscal year. The reason for the sale is to avoid redundancies in the sales structure, as the Meditec Group relies mainly on the ZEISS Group’s sales network in the APAC region.

The carrying amounts of the identified assets as at the reporting date relate to the investment in the company in the amount of €0k.

The investment is allocated as a non-current asset to the “Ophthalmology” SBU and the Asian region.